Q-omics provides the consensus-scored MMACHC profile across patient tissues and cancer cell-line models. MMACHC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MMACHC is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, MMACHC RNA expression shows 18,448 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LUAD, and ACC as cancer lineages where MMACHC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMACHC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMACHC survival associations across molecular data types. MMACHC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMACHC RNA expression–survival associations across cancer types. High MMACHC expression shows unfavorable associations in KICH, LGG and BLCA, but favorable associations in READ, KIRC and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MMACHC RNA expression.
This table summarizes MMACHC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MMACHC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMACHC shows lower tumor expression in THCA and higher tumor expression in LUAD, LUSC, BLCA, STAD and COAD. The LUAD box plot shows higher MMACHC RNA expression in tumor versus normal tissue (log2 FC = +0.985, t-test p < 0.001).
This table shows molecular features associated with MMACHC in patient tissues and cancer cell lines. In patient samples, MMACHC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MMACHC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
